Clinical trials: Stage II Skin Cancer
Untreated Stage III Melanoma or Stage IV Melanoma
Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma
The safety of the combination of ipilimumab with carboplatin/paclitaxel treatment with two different dosing schedules will be investigated in patients with metastatic melanoma.
- Trial name
- NCT01676649
- Testing
- Ipilimumab, Carboplatin, Paclitaxel
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Jewish General Hospital
Advanced Breast Cancer, Metastatic Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg
This study will assess the relationship between fulvestrant dose and efficacy, and determine the dosing regimen as a second line therapy for Japanese postmenopausal women with oestrogen receptor positive advanced breast cancer.
- Trial name
- FINDER I (NCT00305448)
- Testing
- Fulvestrant
- Where
- 35 sites in Japan
- Volunteers
- 143 people
- Sponsor
- AstraZeneca
Breast Cancer
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00824538
- Testing
- sunitinib malate, flow cytometry, immunohistochemistry staining method
- Volunteers
- 13 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00834678
- Testing
- bendamustine, erlotinib, Maintenance erlotinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Melanoma (Skin)
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00991991
- Testing
- gene expression analysis, polymerase chain reaction, polymorphism analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Breast Cancer
Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer
The addition of dimethyldiguanide might increase the efficacy of AI treatment in metastatic breast cancer.
- Trial name
- NCT01654185
- Testing
- AI plus Dimethyldiguanide, Aromatase Inhibitor
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xichun Hu
Breast Cancer
Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02
RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors learn how well triptorelin given together with tamoxifen citrate or exemestane works in lowering estrogen levels.
- Trial name
- SOFT-EST (NCT00975676)
- Testing
- gas chromatography / tandem mass spectometry
- Where
- 24 sites in France, Hungary and 6 more
- Volunteers
- 123 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
This trial evaluates the novel combination of docetaxel with imatinib as first or second line therapy in advanced breast cancer with the aim of achieving higher effectiveness and potentially reducing side effects.
- Trial name
- NCT00193180
- Testing
- Imatinib, Docetaxel
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer Metastatic, Breast Cancer Stage IV
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
After an initial screening phase to identify patients with persistent blood circulating DNA tumors, patients will be enrolled in the treatment phase that was designed as an open-label, multicentre, phase II study, to test the…
- Trial name
- SAFIR3LibHERty (NCT06680596)
- Testing
- trastuzumab derxutecan
- Where
- 40 sites in France
- Volunteers
- 80 people
- Sponsor
- UNICANCER
Melanoma
A Study of GC101 TIL in Advanced Melanoma
98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trial，this trail is expected to be finished in 24 months
- Trial name
- MIZAR-003 (NCT06703398)
- Testing
- GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Juncell Therapeutics
Breast Cancer
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
The purpose of this study is to evaluate the safety and effectiveness of combined treatment with trastuzumab (Herceptin) and bevacizumab (anti-VEGF antibody) in patients with HER2-positive metastatic breast cancer.
- Trial name
- NCT00095706
- Testing
- Bevacizumab (drug), Herceptin (drug)
- Where
- 18 sites in United States
- Volunteers
- 50 people
- Sponsor
- Translational Oncology Research International
Breast Cancer
Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer
Disitamab Vedotin (RC48) contains the novel humanized anti-HER2 antibody conjugated to monomethyl auristatin E (MMAE) via a cleavable linker , which is the first ADC drug that was independently developed by Rongchang Biology .The…
- Trial name
- NCT06000033
- Testing
- Disitamab Vedotin+Anlotinib
- Volunteers
- 35 people
- Sponsor
- Qilu Hospital of Shandong University
Breast Cancer
Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
Primary Objective: To evaluate if low BRCA1 protein expression has a preferential effect on response when metastatic breast cancer patients are treated with DNA damaging chemotherapy agent, compared to historical controls…
- Trial name
- NCT01990352
- Testing
- Pegylated liposomal doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Arizona
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle (Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with…
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00733408
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
- Where
- 17 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Washington
Breast Cancer
Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving anastrozole may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00283608
- Testing
- Single nucleotide polymorphism (SNP), high performance liquid chromatography, measurements by DXA
- Where
- 4 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Mayo Clinic
Breast Cancer
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
The purpose of this study is to compare the safety and efficacy of bi-weekly WH002(Paclitaxel Medium and Long Chain Fat Emulsion Injection,Cholesterol Bound) vs Paclitaxel both followed by bi-weekly Epirubicin and…
- Trial name
- NCT06513364
- Testing
- WH002, paclitaxel injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Wehand-Bio Pharmaceutical Co., Ltd
Metastatic Breast Cancer
Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer
Cancer therapeutics such as chemotherapy may modulate tumor/immune-system interactions in favor of the immune system. Chemotherapy can result in tumor cell death with a resultant increase in tumor antigen delivery to…
- Trial name
- KORNELIA (NCT04061863)
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Seoul National University Hospital
Breast Cancer, Lymphoma
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Filgrastim and stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's…
- Trial name
- NCT00005993
- Testing
- aldesleukin, filgrastim, recombinant human stem cell factor
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer
Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer
The purposes of this study are : to investigate the safety and clinical efficacy of sole therapy with DLBS1425 in suppressing disease-(tumour) progression in subjects with advanced/metastatic breast cancer; and to determine the…
- Trial name
- NCT01006785
- Testing
- DLBS1425
- Where
- 3 sites in Indonesia
- Volunteers
- 15 people
- Sponsor
- Dexa Medica Group
Breast Cancer
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00654836
- Testing
- bevacizumab, Carboplatin, ABI-007
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Loyola University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.